TEMECULA, Calif., May 22, 2017 -- Holy Grail Company (OTC:HGRL) is proud to announce it has posted 2014, 2015, and 2016 audited financials with OTC markets. The company will use these financials in its FORM 10 registration statement.
Additionally, several of the company’s convertible note holders have elected to convert approximately $300,000 worth of their debts into approximately 4 million shares of common stock.
Co-CEO Edward Quiroz stated, “The company continues to grow in the right direction and, as we grow, management will continue to take the proper steps to ensure this company’s success. Holy Grail Company is moving forward and we are excited for new opportunities on the horizon.”
Co-CEO Jason Golec added, “The company’s primary goal is to continue to be a leader within the industry while producing the best Hemp and CBD products on the market. Holy Grail Company plans to accomplish this goal by introducing new products, improving existing products, and utilizing unique marketing and growth strategies. Management is confident that these goals will be obtained due to its outstanding team of employees, consultants, and advisers.”
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Holy Grail Company/ Haenep’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. Holy Grail Company/ Haenep disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact Holy Grail Company/ Haenep’s forward-looking statements, please see Holy Grails/ Haenep’s filings on OTC Markets (OTC:HGRL).
For more information please visit us at: www.HolyGrailCompany.com
Phone: 866-699-5396


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



